

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. NEITHER THESE MATERIALS NOR THE INFORMATION CONTAINED HEREIN CONSTITUTE AN OFFER FOR SALE OF ANY SECURITY.



Medartis Holding AG
Hochbergerstrasse 60E
CH-4057 Basel

PRESS RELEASE

Medartis announces full placement and issuance of over-allotment shares in connection with IPO

Basel, Switzerland, 29 March 2018 – **Medartis Holding AG (SIX: MED)**, a leading manufacturer and provider specialized in medical devices for internal surgical bone fixation, today announces that the **390,625 over-allotment shares were successfully placed and issued in connection with the initial public offering (IPO)**.

Including the 390,625 over-allotment shares representing 15% of the base offering, a total number of 2,994,791 new Medartis shares were placed at a price of CHF 48 per share in connection with the IPO, resulting in gross proceeds for the company of CHF 142.6 million.

Trading in Medartis shares on SIX Swiss Exchange began on 23 March 2018.

Following the IPO and the issuance of the over-allotment shares, Medartis founder and Chairman, Dr. h.c. Thomas Straumann, remains the company's main shareholder with a stake of 47.9%, while Vice-Chairman Dominik Ellenrieder (via NexMed) holds 7.9%, co-founder and CEO Willi Miesch 6.0% and employees 1.3%. The free float amounts to 24.6%, not comprising the shares that are subject to a 12-month lock-up.

Underwriters for the IPO were Zürcher Kantonalbank and Bryan, Garnier & Co, who acted as Joint Global Coordinators and Joint Bookrunners, and Kepler Cheuvreux who acted as Co-Manager. Quarton International acted as financial advisor to the company.

Inquiries

Patrick Christ
Medartis Holding AG
Head Corporate Services
Phone: +41 61 633 34 70
patrick.christ@medartis.com

Karin Rhomberg
Lemongrass Communications AG
Partner
Phone: +41 44 202 52 65
karin.rhomberg@lemongrass.agency

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. NEITHER THESE MATERIALS NOR THE INFORMATION CONTAINED HEREIN CONSTITUTE AN OFFER FOR SALE OF ANY SECURITY.

About Medartis

Founded in 1997 and headquartered in Basel, Switzerland, Medartis is one of the world's leading manufacturers and providers of medical devices for surgical fixation of bone fractures and osteotomies for the craniofacial region as well as for upper and lower extremities. Medartis employs over 480 individuals across its 11 locations, and Medartis products are sold in 44 countries globally. For patients' welfare, Medartis is committed to providing surgeons and operating theatre personnel with the most innovative titanium implants and instruments as well as best in class services that represent advances in osteosynthesis. For more information, please visit www.medartis.com.

Disclaimer

This announcement is not an offer to sell or a solicitation of any offer to buy any securities issued by Medartis Holding AG (the "Company") in any jurisdiction where such offer or sale would be unlawful, and the announcement and the information contained herein are not for distribution or release, directly or indirectly, in or into such jurisdictions.

This announcement and the information contained herein are not for distribution in or into the United States of America (including its territories and possessions, any state of the United States of America and the District of Columbia) (the "United States"). This document does not constitute, or form part of, an offer to sell, or a solicitation of an offer to purchase, any securities of the Company in the United States. The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. Any securities sold in the United States will be sold only to "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) in reliance on an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.

This announcement is not an issuance or listing prospectus or a similar document in the sense of article 652a, article 752 and/or article 1156 of the Swiss Code of Obligations or articles 27 et seq. of the Listing Rules of the SIX Swiss Exchange and was not reviewed by any competent authority.

In any member state of the European Economic Area ("EEA Member State"), this announcement is only addressed to and is only directed at persons in that EEA Member State who are "qualified investors" within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC) ("Qualified Investors").

In addition, in the United Kingdom, this announcement is being distributed only to, and is directed only at, Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended and Qualified Investors falling within Article 49(2)(a) to (d) of such Order, and (ii) to whom it may otherwise lawfully be communicated (all such persons together being referred to as "Relevant Persons").

Zürcher Kantonalbank and Bryan Garnier & Co (each a "Manager", together the "Managers") and their affiliates are acting exclusively for the Company and no one else in connection with the offering. They will not regard any other person as their respective clients in relation to the offering and will not be responsible to anyone other than the Company and for providing the protections afforded to their respective clients, nor for providing advice in relation to the offering, the contents of this announcement or any transaction, arrangement or other matter referred to herein. In connection with the offering, the Managers and any of their affiliates, acting as investors for their own accounts, may subscribe for or purchase shares and in that capacity may retain, purchase, sell, offer to sell or otherwise deal for their own accounts in such shares and other securities of the Company or related investments in connection with the offering or otherwise. Accordingly, references in the offering memorandum, to the shares being issued, offered, subscribed, acquired, placed or otherwise dealt in should be read as including any issue or offer to, or subscription, acquisition, placing or dealing by, such Managers and any of their affiliates acting as investors for their own accounts.

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. NEITHER THESE MATERIALS NOR THE INFORMATION CONTAINED HEREIN CONSTITUTE AN OFFER FOR SALE OF ANY SECURITY.

The Managers do not intend to disclose the extent of any such investment or transactions otherwise than in accordance with any legal or regulatory obligations to do so. Zürcher Kantonalbank will not act as Manager in connection with any placements within the United States.

Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and that can be identified by words such as “believe”, “expect”, “anticipate”, “intends”, “estimate”, “will”, “may”, “continue”, “should”, and similar expressions. The forward-looking statements in this announcement are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice.